WSJ
08 Jun 2026, 05:47 UTC · 8h ago
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
Top 1 mover · tap to explore
WSJ
08 Jun 2026, 05:47 UTC · 8h ago
Top 1 mover · tap to explore
Story key points
2 claims · impact-rated
Roche is paying Nurix an upfront payment of $700 million. — Large upfront payments provide immediate non-dilutive capital to the smaller partner and signal high confidence in the asset's value.
+0.60Roche and Nurix will split development costs 60-40, with Roche bearing the majority. — Cost-sharing reduces the financial risk for Nurix while demonstrating Roche's commitment to the project's success.
+0.20Ticker attribution
Model heads
The company is receiving a substantial $700 million upfront payment.
Continue reading
6 related stories
The company is incurring significant upfront costs and the majority of development expenses for the partnership.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 10 offered
Barrons
4h ago
